TrialsgrambetaRCTs are beautiful
TCT 2026Presented Sun 1 Nov · 11:29 GMT-8Late-Breaking Clinical Trials: Session I, in Collaboration with The LancetAll Late-Breaking trials →

HD-PCI

2026

A Randomized Trial of Higher vs. Lower Dose Heparin for PCI (HD-PCI)

In patients undergoing elective PCI, a higher-dose unfractionated heparin policy did not reduce death, myocardial infarction or target vessel revascularisation at 30 days, or change major bleeding, compared with a lower-dose heparin policy.

Result

Efficacy: Death, myocardial infarction or target vessel revascularisation within 30 daysHR 1.29 (95% CI 0.89-1.87)

Safety: Major bleedingHR 1.03 (95% CI 0.70-1.52)

Below 1 favours a higher-dose unfractionated heparin policy, above 1 favours a lower-dose heparin policy.

Event rates a higher-dose unfractionated heparin policy 1.2% vs a lower-dose heparin policy 1.0% (death, myocardial infarction or target vessel revascularisation within 30 days)

Also reported: An activated clotting time was recorded in 39.6% of procedures.

Original publication
Subtopic
Periprocedural anticoagulation
Design
Cluster-randomised crossover trial of hospital-wide heparin policies for elective PCI (Population Health Research Institute, Canada). Each hospital alternates between a 100 U/kg and a 70 U/kg bolus of unfractionated heparin; outcomes come from linked PCI registries
Enrolled
11,619 patients
Source
Jolly S, et al. Presented at TCT 2026, 1 November. Reported by TCTMD (CRF). Not yet published.

Discussion & critique

In a large cluster-crossover trial of elective PCI, a higher-dose heparin policy did not reduce 30-day ischaemic events or change major bleeding, and the source reports that the confidence interval excluded the benefit the trial was powered for. Follow-up was limited to 30 days, event rates were low, and centres rather than patients were randomised, so the trial compares hospital policies rather than individual dosing. The report gives hazard ratios without P values and does not describe blinding, adherence to the assigned policy or a net clinical outcome. These figures come from a news report of the presentation, not a peer-reviewed paper.